🇺🇸 PF-06700841 45 mg in United States

PF-06700841 45 mg (pf-06700841-45-mg) regulatory status in United States.

Marketing authorisation

FDA

  • Status: approved

Pricing & reimbursement

PF-06700841 45 mg in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Neuroscience approved in United States

Frequently asked questions

Is PF-06700841 45 mg approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for PF-06700841 45 mg in United States?

Pfizer is the originator. The local marketing authorisation holder may differ — check the official source linked above.

What does PF-06700841 45 mg cost in United States?

annual_list: USD 0.00 per year. Final patient cost depends on reimbursement and any patient access scheme.